​​​Our History​

​

In 2003 Princeton Biotechnology was incorporated.  Since then our general focus has been to develop innovative medicines that are both eff​ective and safe, and that particularly could be used to make a significant contribution to therapeutic communities that are under-served by present day medicine.  Burn wound victims worldwide comprise one such underserved group that we wanted to help.  In the USA for example, most burn victims are under-treated for their pain, which is considered one of the worst types of pain. 

​

To make a significant contribution to this relatively small marketplace of burn victims would prove to be a major challenge for our drug development team at Princeton Biotechnology.  ​​​Yet, in time, their sustained pursuit of an effective, fast acting and safe burn pain and wound healing solution led to the development of AHEALON®. 

​

​

AHEALON® has the potential to become one of most prescribed Prescription Drugs of the 21st Century

​

​AHEALON® was initially in development as an easy to use, generally topically applied prescription drug for burn victims.  To assist in the extremely complex burn wound healing process, which  necessitated for example accelerated epithelialization, besides its 6-in-1 core functionality (listed below), AHEALON® was also designed to initiate, stimulate and accelerate a number of simultaneous wound healing cascades within the body, while also acting, if needed, to quickly stop pain in seconds to within a few minutes.

​​

At the end of its development process AHEALON® ultimately incorporated 6 major functions, all of which work in concert to expeditiously:

 

           1.  Stop/mitigate pain

           2.  Reduce inflammation

           3.  Fight infection

           4.  Stimulate healing

​​​           5.  Stop/mitigate scar tissue

​​           6.  Provide wound bed moisturization​

​

After a review of the large number of functions that were built into AHEALON® to deal with all aspects of the complete burn wound healing process, it became apparent that AHEALON® could be effectively prescribed for many, if not all other types of wounds and/or painful conditions.  This universality of use brought the realization that AHEALON® had the potential to become one

of the top breakthrough prescription drugs of the 21st Century.  

​

​​​

​AHEALON® can help

simplify pain management

and wound healing protocols

​

​The ​​6-in-1 core functions of AHEALON® allow it​ to be effectively prescribed and used throughout the complete wound healing process, which therefore can help to significantly simplify the practice of pain management and wound healing protocols.

​

​

​AHEALON® is a GRAS product, and features no unwanted side effects

 

​​​​​

​​The design of AHEALON® as an effective and fast acting medicine was careful to include attributes that were consistent with our Princeton Biotechnology ​safe medicine focus.  Although there is the possibility of initial stinging, AHEALON® is:

​"Generally Regarded as Safe" (GRAS),

​​nontoxic and hypoallergenic, except for the possibility of a patient's extreme sensitivity to sulfur and silver and other AHEALON® ingredients.

​​

​

​In Summary

​

​B​y successfully addressing the specific and very demanding needs of the small therapeutic marketplace of burn victims, which necessitated its revolutionary 6-in-1 dynamic core functionality, AHEALON® therein ultimately positioned itself to be able to therapeutically address a substantial number of very large medical marketplaces. 

​

 

​​AHEALON®  USA FDA NDC 52793-700-02. 

​

​

The 20 AHEALON® attributes are exceptional.

​